WS #10122
Pfizer reaffirms FY26 guidance after CFO transition, calming investor concerns.
Pfizer Reaffirms Guidance
Pfizer reaffirms FY26 guidance after CFO transition, calming investor concerns.
Pfizer reaffirms FY26 guidance after CFO transition, calming investor concerns.
Pfizer reaffirms FY26 guidance after CFO transition, calming investor concerns.